T. Göksel (Izmir, Turkey), D. Heigener (Rotenburg (Wuemme), Germany)
Lung cancer survival in never smokers. Results from the LCRINS study
A. Casal (Santiago de Compostela, Spain), M. Torres (Vigo, Spain), I. Parente (Orense, Spain), M. Provencio (Madrid, Spain), A. Golpe (Santiago de Compostela, Spain), C. Montero (A Coruña, Spain), I. Vidal (A Coruña, Spain), V. Leiro (Vigo, Spain), C. Martínez (Oviedo, Spain), O. Castro (Lugo, Spain), A. Fernández (Vigo, Spain), L. Valdés (Santiago de Compostela, Spain), A. Ruano (Santiago de Compostela, Spain)
|   |
Nationwide real-world cohort study of first line TKI treatment in epidermal growth factor receptor mutated non-small cell lung cancer.
R. Gijtenbeek (Leeuwarden, Netherlands), R. Damhuis (Utrecht, Netherlands), H. Groen (Groningen, Netherlands), A. Van Der Wekken (Groningen, Netherlands), W. Van Geffen (Leeuwarden, Netherlands)
| |
Real-life effectiveness of first-line treatments in NSCLC patients stage IIIB/IV– data from the Czech TULUNG Registry.
K. Brat (Brno, Czech Republic), M. Bratova (Brno, Czech Republic), J. Skrickova (Brno, Czech Republic), M. Barinova (Brno, Czech Republic), K. Hurdalkova (Brno, Czech Republic), M. Pesek (Pilsen, Czech Republic), M. Svaton (Pilsen, Czech Republic), L. Havel (Prague, Czech Republic), M. Cernovska (Prague, Czech Republic), L. Koubkova (Prague, Czech Republic), M. Hrnciarik (Hradec Kralove, Czech Republic), J. Krejci (Prague, Czech Republic), J. Kultan (Olomouc, Czech Republic), O. Fischer (Olomouc, Czech Republic), M. Zemanova (Prague, Czech Republic), H. Coupkova (Brno, Czech Republic), T. Tuzova (Jihlava, Czech Republic), D. Dolezal (Usti nad Labem, Czech Republic), M. Safanda (Prague, Czech Republic)
| |
The gendered Experience of mesothelioma study (GEMS): findings from a survey data analysis
M. Senek (Sheffield , United Kingdom), A. Tod (Sheffield , United Kingdom), S. Robertson (Sheffield , United Kingdom)
| |
Natural course of asymptomatic malignant pleural effusion in non-small-cell lung cancer patients: a multicenter retrospective study
J. Eom (Busan, Republic of Korea), J. Roh (Busan, Republic of Korea), I. Kim (Busan, Republic of Korea), H. Seol (Busan, Republic of Korea), M. Lee (Busan, Republic of Korea)
| |
Epidermal growth factor receptor (EGFR) gene mutation testing prior to tyrosine kinase inhibitors (TKI) treatment – prospective data from the Czech TULUNG registry
J. Skricková (Brno, Czech Republic), P. Májková (Brno, Czech Republic), M. Barinová (Brno, Czech Republic), M. Bratová (Brno, Czech Republic), M. Pešek (Plzen, Czech Republic), M. Svaton (Plzen, Czech Republic), V. Kolek (Olomouc, Czech Republic), O. Fišer (Olomouc, Czech Republic), L. Koubková (Praha, Czech Republic), A. Benejová (Brno, Czech Republic), O. Venclícek (Brno, Czech Republic), M. Cernovská (Praha, Czech Republic), L. Havel (Praha, Czech Republic), M. Hrnciarik (Hradec Králové, Czech Republic), J. Roubec (Ostrava, Czech Republic), Z. Milada (Praha, Czech Republic), P. Opálka (Praha, Czech Republic), J. Krejcí (Praha, Czech Republic), D. Krejcí (Praha, Czech Republic), H. Coupková (Brno, Czech Republic), Z. Merta (Brno, Czech Republic)
| |
Efficacy and prognostic factors of first-line afatinib treatment for the EGFR-mutated non-small cell lung cancer in the real world
T. Chiu (Taoyuan, Taiwan), C. Huang (Taoyuan, Taiwan), C. Kuo (Taoyuan, Taiwan)
| |
Treatment sequencing in NSCLC EGFR+ – real-world data
A. Fernandes (Matosinhos, Portugal), M. Dias (Matosinhos, Portugal), D. Coutinho (Matosinhos, Portugal), E. Silva (Matosinhos, Portugal), T. Costa (Matosinhos, Portugal), S. Campainha (Matosinhos, Portugal), S. Conde (Matosinhos, Portugal), A. Barroso (Matosinhos, Portugal)
| |
Clinical and molecular features of V600E and non-V600E BRAF mutations in NSCLC – a retrospective monocentric observational study
C. Lips (Berlin, Germany), G. Rafflenbeul (Berlin, Germany), T. Blum (Berlin, Germany), J. Kollmeier (Berlin, Germany), D. Misch (Berlin, Germany), M. Schäfer (Berlin, Germany), S. Stephan-Falkenau (Berlin, Germany), A. Streubel (Berlin, Germany), S. Thiel (Berlin, Germany), T. Mairinger (Berlin, Germany), T. Bauer (Berlin, Germany)
| |
Study of current trend of thoracic malignancy in young adults at a tertiary care center
D. Bajaj (Lucknow (Uttar Pradesh), India), S. Kant (Lucknow (Uttar Pradesh), India), R. Tyagi (Lucknow (Uttar Pradesh), India), J. Bajpai (Lucknow (Uttar Pradesh), India), A. Dubey (Lucknow (Uttar Pradesh), India), R. Kushwaha (Lucknow (Uttar Pradesh), India), A. Verma (Lucknow (Uttar Pradesh), India), K. Vignesh (Lucknow (Uttar Pradesh), India), M. Asnani (Lucknow (Uttar Pradesh), India)
| |
Non small cell lung cancer: options and outcome of treatment beyond second line
T. Erdélyi (Budapest, Hungary), A. Bíró (Budapest, Hungary), Z. Matics (Budapest, Hungary), L. Koch (Budapest, Hungary), L. Tamási (Budapest, Hungary), V. Müller (Budapest, Hungary)
| |
Pembrolizumab versus nivolumab as second and further line treatment in non-small cell lung cancer; a retrospective single-centre study
M. Mitsogianni (Athens, Greece), D. Vassos (Athens, Greece), I. Kotteas (Athens, Greece), V. Patriarcheas (Athens, Greece), A. Vassias (Athens, Greece), L. Stournara (Athens, Greece), I. Tourkantonis (Athens, Greece), D. Stefanou (Athens, Greece), A. Charpidou (Athens, Greece), K. Syrigos (Athens, Greece)
| |
Osimertinib as a second-line treatment for EGFR-mutated non-small cell lung cancer: the experience of a Pulmonology department
D. Dantas Barreto Rodrigues (Braga, Portugal), C. Lacerda (Braga, Portugal), F. Aguiar (Braga, Portugal), M. Araújo (Braga, Portugal), D. Pimenta (Braga, Portugal), L. Ferreira (Braga, Portugal)
| |
Progression after osimertinib in EGFR T790M-mutated non-small cell cancer patients
D. Araújo Barros Coelho (Porto, Portugal), C. Sousa (Porto, Portugal), M. Jacob (Porto, Portugal), L. Almeida (Porto, Portugal), D. Araújo (Porto, Portugal), H. Novais-Bastos (Porto, Portugal), A. Magalhães (Porto, Portugal), C. Souto Moura (Porto, Portugal), L. Cirnes (Porto, Portugal), V. Hespanhol (Porto, Portugal), H. Queiroga (Porto, Portugal), G. Fernandes (Porto, Portugal)
| |
IMPORTANT BENEFITS OF EBUS-TBNA IN ASSESSING PD-L1 EXPRESSION IN NSCLC
G. Vargas Centanaro (Madrid, Spain), E. Forcen (Madrid, Spain), B. Morales (Madrid, Spain), J. Alvarez-Sala (Madrid, Spain), M. Calle (Madrid, Spain), M. Bernabe (Madrid, Spain)
| |
Clinical and computed tomography features (CT) of lung adenocarcinoma with epidermal growth factor receptor (EGFR) mutation and anaplastic lymphoma kinase (ALK) status
R. Castañon Perez (Burgos, Spain), G. Gutiérrez Herrero (Burgos, Spain), H. Álvarez Martínez (Burgos, Spain), P. Lozano Cuesta (Burgos, Spain), O. Sánchez Martin (Burgos, Spain), M. Arias Fuente (Burgos, Spain), L. Castallanos Romero (Burgos, Spain), L. Rodríguez Pascual (Burgos, Spain)
| |
Effectiveness of oral metronomic Vinorelbine versus Docetaxel as second-line treatment in Non-Small Cell Lung Cancer patients in real life
A. Nikolakopoulou (Athens, Greece), K. Tzimopoulos (Athens, Greece), E. Tsaroucha (Athens, Greece), K. Kavvada (Athens, Greece), A. Rapti (Athens, Greece)
| |